14.06.2016 • News

Carbogen Amcis Expanding Swiss Capacity

(c) Westend61/Getty Images
(c) Westend61/Getty Images

Carbogen Amcis, a Swiss company specialized in process development and manufacturing of Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry, is expanding its   operations in Bubendorf, Switzerland, to take account of a “significant and continuous increase in customers’ demand for additional capacity, including demand for labs and small scale development.”

The company has purchased a 3,360 m2 multi-story building on 5,200 m² of land and will convert it to its own specifications. When operations begin in January 2017, the premises will house laboratory, production, storage and office areas and provide a set of clean-room GMP compliant suites.

Stephan Fritschi, vice president Operations at Carbogen Amcis, said the immediate proximity to the company’s current headquarters and its larger scale production site in Bubendorf, Switzerland, is “ideal,” as it will allow a significantly expansion of laboratory capacity for highly potent development and small scale production as well as analytical support.

In the near future, the company said it plans to introduce a number of additional capabilities including commercial manufacture of ADCs and additional Cat 4 (ng OEL) development capacity.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Free Virtual Event

Batteries and Hydrogen: Competitors or Partners?
CHEManager Spotlight

Batteries and Hydrogen: Competitors or Partners?

17 September 2026 | Reserve your spot to learn where solid-state batteries and green hydrogen are headed—and how leading teams are turning them into scalable energy storage solutions.

most read